ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1865

Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study

Neda Amiri1, Natasha Dehghan2, Eric C. Sayre3, Kamran Shojania1 and J. Antonio Avina-Zubieta4, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Cerebrovascular disease, myocardial involvement and vasculitis, Wegener's granulomatosis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose

Limited literature is available on the incidence of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Granulomatosis with Polyangiitis (GPA).  We assessed the risk of MI and CVA in cases with GPA compared to controls from the general population using hospitalization databases and physician billings that encompasses the entire province of British Columbia, Canada. We further determined the time trend risks of MI and CVA since diagnosis of GPA.

Methods

Our data included all visits to health professionals and all hospital admissions from 1990 to 2010 as well as all dispensed medication from 1996 to 2010 for all individuals.

We conducted a retrospective matched cohort study among new cases with GPA meeting a pre-defined criteria as follows: a) diagnosis of GPA (ICD-9-CM 446.4) in adults on at least two visits within a two-year period between 1996 and 2010 by a non-rheumatologist physician; b) diagnosis of GPA on at least one visit by a rheumatologist or from hospitalization; c) absence of a prior GPA diagnosis between January 1990 and December 1995 (to ensure incident GPA cases). Ten controls matched by birth year, sex and calendar year of follow-up were selected from the general population. Incident MI and CVA events based on hospitalization or death certificate were recorded as an outcome. We estimated relative risks (RRs) comparing GPA with age-, sex- and entry time-matched comparison cohorts, adjusting for potential cardiovascular risk factors. Sensitivity analyses were conducted to assess for unmeasured confounders (e.g. smoking).

Results

Among 640 incident cases of GPA (54.2% female, mean age 58.6), 28 developed a first time MI and 25 CVA events with an incident rate (IR) of 13.9 and 12.3 per 1000 person-years, respectively. Compared with the age, sex, and entry-matched controls, the incidence rate ratio (IRR) were 3.3 (95% CI 2.1-5.0) and 3.2 (95% CI 2.0-5.1) for MI and CVA respectively. The risk of developing MI and CVA was highest within the first year following diagnosis of GPA, decreasing over time and persisting after 5 years (see table).  After adjusting for covariates, the results remained significant for both MI and CVA. The results also remained statistically significant after adjusting for the potential impact of unmeasured confounders (adjusted RRs ranging between 2.57 and 3.84 in all sensitivity analyses).

Conclusion

This large general population-based study found an increased an increased risk of MI and CVA in patients with GPA. Furthermore, the risk is highest in the first year of disease and decreases subsequently persisting at 5 years of follow up.  Our results support increased monitoring for cardiovascular disease in patients with GPA, including management of traditional risk factors to reduce this risk.

Table: Risk of Incident MI and CVA according to GPA Status

GPA

N = 608

Non-GPA

N = 6,169

Cases of MI, n

28

108

Incidence Rate/1000 PY

13.9

4.2

Age-, sex-, and entry time-matched RRs (95% CI)

3.3 (2.1-5.0)

1.0

1 year of disease duration

6.0 (2.7-12.7)

1.0

2 years

3.9 (1.9-7.4)

1.0

3 years

3.1 (1.6-5.6)

1.0

4 years

3.5 (2.0-5.9)

1.0

5 years

3.4 (2.0-5.6)

1.0

Multivariable RR (95% CI)

3.9 (2.2-6.7)

1

GPA

N = 623

Non-GPA

N = 6,307

Cases of CVA, n

25

99

Incidence Rate/1000 PY

12.3

3.8

Age-, sex-, and entry time-matched RRs (95% CI)

3.2 (2.0-5.1)

1.0

1 year of disease duration

7.1 (3.3-14.5)

1.0

2 years

5.1 (2.7-9.2)

1.0

3 years

4.5 (2.5-7.8)

1.0

4 years

4.0 (2.3-6.8)

1.0

5 years

4.1 (2.4-6.7)

1.0

Multivariable RR (95% CI)

3.1 (1.7-5.7)

1.0


Disclosure:

N. Amiri,
None;

N. Dehghan,
None;

E. C. Sayre,
None;

K. Shojania,
None;

J. A. Avina-Zubieta,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-myocardial-infarction-and-cerebrovascular-accidents-after-diagnosis-of-granulomatosis-with-polyangiitis-a-general-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology